Harish Shantharam

Chief Financial Officer at ALX Oncology

Speaker

Harish Shantharam has served as Chief Financial Officer since January 2025. He joined ALX Oncology from CymaBay Therapeutics, Inc., where he helped guide the company in its transition towards late-stage development and commercial readiness and through its $4.3 billion acquisition by Gilead Sciences, Inc. Earlier in his career, he served in roles of increasing responsibility and scope at Gilead Sciences, including as Vice President and Head of Global Commercial Finance, where he led the financial operations supporting a global $20 to $30 billion-dollar revenue business. Prior to joining Gilead, Mr. Shantharam served in various roles of increasing responsibility driving forecasting, commercial analytics and business development at Amgen. Mr. Shantharam holds an MBA in finance from UCLA Anderson School of Management and a graduate degree in Industrial Engineering from the University of Texas at Arlington. He is also a CFA charter holder.